American Renal Associates Holdings Inc. (NYSE:ARA) shares dropped 1.7% during mid-day trading on Thursday . The company traded as low as $26.05 and last traded at $26.35, with a volume of 77,471 shares traded. The stock had previously closed at $26.80.

ARA has been the topic of a number of research reports. SunTrust Banks Inc. initiated coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set a “buy” rating and a $34.00 price target on the stock. Wells Fargo & Co. initiated coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set an “outperform” rating on the stock. Leerink Swann restated an “outperform” rating on shares of American Renal Associates Holdings in a research note on Monday, May 16th. Goldman Sachs Group Inc. initiated coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set a “neutral” rating and a $30.00 price target on the stock. Finally, Barclays PLC initiated coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set an “overweight” rating and a $33.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $32.50.

The company has a market cap of $585.47 million and a P/E ratio of 13.42. The firm’s 50-day moving average is $0.00 and its 200 day moving average is $0.00.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings results on Thursday, May 12th. The company reported $0.16 earnings per share (EPS) for the quarter. The firm had revenue of $172.10 million for the quarter, compared to the consensus estimate of $149.30 million. Analysts predict that American Renal Associates Holdings Inc. will post $0.88 earnings per share for the current fiscal year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.